Template:Oral hypoglycemics and insulin analogs: Difference between revisions
Content deleted Content added
typo |
WHO EML |
||
| Line 20: | Line 20: | ||
| group3 = ''long-acting'' |
| group3 = ''long-acting'' |
||
| list3 = |
| list3 = |
||
*[[Insulin detemir]] |
*[[Insulin detemir]]<sup>#</sup> |
||
*[[Insulin glargine]] ([[Insulin glargine/lixisenatide|+lixisenatide]]) |
*[[Insulin glargine]]<sup>#</sup> ([[Insulin glargine/lixisenatide|+lixisenatide]]) |
||
*[[NPH insulin]] |
*[[NPH insulin]] |
||
*[[Lente insulin]]<sup>‡</sup> |
*[[Lente insulin]]<sup>‡</sup> |
||
| Line 159: | Line 159: | ||
*[[Canagliflozin]] |
*[[Canagliflozin]] |
||
*[[Dapagliflozin]] |
*[[Dapagliflozin]] |
||
*[[Empagliflozin]] |
*[[Empagliflozin]]<sup>#</sup> |
||
*[[Ertugliflozin]] |
*[[Ertugliflozin]] |
||
*[[Ipragliflozin]] |
*[[Ipragliflozin]] |
||
Revision as of 03:55, 11 October 2021
This template's initial visibility currently defaults to autocollapse, meaning that if there is another collapsible item on the page (a navbox, sidebar, or table with the collapsible attribute), it is hidden apart from its title bar; if not, it is fully visible.
To change this template's initial visibility, the |state= parameter may be used:
{{Oral hypoglycemics and insulin analogs|state=collapsed}}will show the template collapsed, i.e. hidden apart from its title bar.{{Oral hypoglycemics and insulin analogs|state=expanded}}will show the template expanded, i.e. fully visible.